Natera, Inc. (NTRA)
The price, the headline numbers and the latest news, in one place.
Natera, Inc. (NTRA) Stock Price, Analysis & Data
| Bid | 298.3 |
| Market Cap | 47.3B |
| Revenue (ttm) | 2.71B |
| Net Income (ttm) | -192M |
| 1.53 | |
| -1.35 | |
| n/a | |
| -3679.15 | |
| P/B (ttm) | 25.88 |
| P/S (ttm) | 17.47 |
| Earnings Date | Nov 5, 2026 |
| Ask | 353.21 |
| Volume | 968,221 |
| Avg. Volume (20D) | 1,385,123 |
| Open | 323.92 |
| Previous Close | 327.67 |
| Day's Range | 323.42 - 329.05 |
| 52-Week Range | 157.43 - 343.18 |
| Analyst | Strong<br>Buy |
| Price Target | 350 (6.65%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About NTRA
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a heredi...
Financial Performance
In 2025, Natera's revenue was 2.31B, an increase of 35.9% compared to the previous year's 1.7B. Earnings were -208.16M, an increase of 9.31%.
Financial StatementsAnalyst Forecast
According to 21 analyst ratings, the average rating for NTRA stock is "Strong Buy". The 12-month stock price forecast is 350, which is upside of 6.65% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $752.75M misses estimates by $0, with 37.71% YoY growth.
- EPS of -0.47 exceeds estimates by 0.06, with 36.49% YoY growth.
Analysts project revenue of ... Upgrade
